Impact of adjuvant treatment on survival in patients with 2023 FIGO stage IIC endometrial cancer: a retrospective analysis from two tertiary centers in Korea and Taiwan.,Journal of Gynecologic Oncology

当前位置： X-MOL 学术 › J. Gynecol. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Impact of adjuvant treatment on survival in patients with 2023 FIGO stage IIC endometrial cancer: a retrospective analysis from two tertiary centers in Korea and Taiwan.
Journal of Gynecologic Oncology ( IF 3.9 ) Pub Date : 2023-12-12 , DOI: 10.3802/jgo.2024.35.e33
Yoo-Young Lee, Yen-Ling Lai, Myeong-Seon Kim, Koping Chang, Hyun-Soo Kim, Wen-Fang Cheng, Yu-Li Chen

In early-stage endometrial cancer, aggressive histologic types (grade 3 endometrioid, serous, clear cell, carcinosarcomas, undifferentiated, mixed, and other unusual types) are associated with an increased risk of distant metastases and worse survival. However, the optimal adjuvant treatment for these patients remains controversial. The present study investigated the outcomes of different adjuvant treatments in patients with 2023 FIGO stage IIC endometrial cancer.

更新日期：2023-12-12

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>